Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Ginsenoside-Rd for Acute Ischemic Stroke

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態完了
スポンサー
Xijing Hospital

キーワード

概要

The purpose of this study is to evaluate the efficacy and safety of ginsenoside-Rd for acute ischemic stroke.

説明

A major contributor to brain injury after stroke is disordered inward flow of Ca2+ and its toxic accumulation in the nervous system following cerebral ischemia. Ginsenoside-Rd, a purified component from total saponins of Panax notoginseng, has a molecular formula of C48H82O18•3H2O with a molecular weight of 1001.2. Ginsenoside-Rd has been shown to inhibit receptor-operated Ca2+ influx through receptor-and-store-operated Ca2+ channels (ROCC) , attenuate oxidative stress in stroke, reduce the size of the cerebral infarction and preserve brain functioning in animal models of acute ischemic stroke.

日付

最終確認済み: 11/30/2007
最初に提出された: 12/26/2007
提出された推定登録数: 01/09/2008
最初の投稿: 01/10/2008
最終更新が送信されました: 08/29/2010
最終更新日: 08/31/2010
実際の研究開始日: 08/31/2005
一次完了予定日: 05/31/2006
研究完了予定日: 08/31/2006

状態または病気

Ischemic Stroke

介入/治療

Drug: ginsenoside-Rd 10mg

Drug: placebo

Drug: ginsenoside-Rd 20mg

段階

段階 2

アームグループ

介入/治療
Experimental: ginsenoside-Rd 10mg
both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
Drug: ginsenoside-Rd 10mg
infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
Placebo Comparator: placebo
2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
Drug: placebo
infusion placebo (group B)once a day and continued for 14 days
Experimental: ginsenoside-Rd 20mg
2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed
Drug: ginsenoside-Rd 20mg
infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days

適格基準

研究の対象となる年齢 18 Years に 18 Years
研究に適格な性別All
健康なボランティアを受け入れるはい
基準

Inclusion Criteria:

- between 18 to 75 years

- the first episode

- from onset to admission within 72 hours

- NIHSS scores:5~22

Exclusion Criteria:

- had other intracranial pathologies (e.g., tumor, infection)

- had a neurologic or psychiatric disease

- had a coexisting condition that limited their life expectancy

- had significant drug or alcohol misuse

- had high-grade carotid artery stenosis for which surgery was planned

- were pregnant or nursing

- participated in a clinical trial with an investigational drug or device within the past 3 months

- were unlikely to be available for follow-up

結果

主な結果の測定

1. NIHSS scores [15±1 days]

二次的な結果の測定

1. NIHSS scores [8 days]

2. the Barthel index [8 days]

3. the Barthel index [15 days]

4. the modified Rankin scale [15 days]

5. the modified Rankin scale [90 days]

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge